Ontology highlight
ABSTRACT:
SUBMITTER: Poklepovic A
PROVIDER: S-EPMC3844155 | biostudies-literature | 2013 Aug
REPOSITORIES: biostudies-literature
Poklepovic Andrew A Youssefian Leena E LE Winning Mary M Birdsell Christine A CA Crosby Nancy A NA Ramakrishnan Viswanathan V Ernstoff Marc S MS Roberts John D JD
Investigational new drugs 20130113 4
<h4>Purpose</h4>Preclinical studies in human melanoma cell lines and murine xenograft tumor models suggest that the proteasome inhibitor bortezomib enhances the activity of the cytotoxic agent dacarbazine. We performed a phase I trial of bortezomib and dacarbazine in melanoma, soft tissue sarcoma, and amine precursor uptake and decarboxylation tumors. The primary objective was to identify recommended phase II doses for the combination.<h4>Experimental design</h4>Bortezomib and dacarbazine were b ...[more]